| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes
|
Ruano, Luis
|
|
2017
|
23 |
9 |
p. 1258-1267
|
artikel
|
| 2 |
Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder
|
Yamout, Bassem I
|
|
2017
|
23 |
9 |
p. 1297-1300
|
artikel
|
| 3 |
Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis
|
D’Ambrosio, Alessandro
|
|
2017
|
23 |
9 |
p. 1194-1203
|
artikel
|
| 4 |
Clinical–radiological–pathological spectrum of central nervous system–idiopathic inflammatory demyelinating disease in the elderly
|
Tobin, W Oliver
|
|
2017
|
23 |
9 |
p. 1204-1213
|
artikel
|
| 5 |
Corrigendum
|
|
|
2017
|
23 |
9 |
p. NP1
|
artikel
|
| 6 |
Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors
|
Bsteh, Gabriel
|
|
2017
|
23 |
9 |
p. 1241-1248
|
artikel
|
| 7 |
Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – Commentary
|
Corboy, John R
|
|
2017
|
23 |
9 |
p. 1192-1193
|
artikel
|
| 8 |
Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – NO
|
Tobin, W Oliver
|
|
2017
|
23 |
9 |
p. 1190-1192
|
artikel
|
| 9 |
Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES
|
Kister, Ilya
|
|
2017
|
23 |
9 |
p. 1188-1190
|
artikel
|
| 10 |
Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis
|
Planche, Vincent
|
|
2017
|
23 |
9 |
p. 1214-1224
|
artikel
|
| 11 |
Importance of early treatment initiation in the clinical course of multiple sclerosis
|
Kavaliunas, Andrius
|
|
2017
|
23 |
9 |
p. 1233-1240
|
artikel
|
| 12 |
Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS
|
de Flon, Pierre
|
|
2017
|
23 |
9 |
p. 1249-1257
|
artikel
|
| 13 |
“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
|
Giovannoni, Gavin
|
|
2017
|
23 |
9 |
p. 1179-1187
|
artikel
|
| 14 |
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod
|
Ghadiri, Mahtab
|
|
2017
|
23 |
9 |
p. 1225-1232
|
artikel
|
| 15 |
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod
|
Warnke, Clemens
|
|
2017
|
23 |
9 |
p. 1176-1178
|
artikel
|
| 16 |
Sexual functioning in multiple sclerosis: Relationships with depression, fatigue and physical function
|
Young, Carolyn A
|
|
2017
|
23 |
9 |
p. 1268-1275
|
artikel
|
| 17 |
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests
|
Saccà, Francesco
|
|
2017
|
23 |
9 |
p. 1289-1296
|
artikel
|
| 18 |
The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis
|
Gabilondo, Iñigo
|
|
2017
|
23 |
9 |
p. 1276-1288
|
artikel
|
| 19 |
Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?
|
Kira, Jun-ichi
|
|
2017
|
23 |
9 |
p. 1300-1302
|
artikel
|
Tijdschrift beschrijving